An Overview of Vigil Personalized Engineered Autologous Tumor Cells in Ovarian Cancer
Rodney P. Rocconi, MD, chief of Gynecologic Oncology Service, associate director for Clinical Research, professor of Interdisciplinary Clinical Oncology, discusses a phase I trial of Vigil personalized engineered autologous tumor cells in ovarian cancer during the 2018 Society of Gynecologic Oncology Annual Meeting.
Rodney P. Rocconi, MD, chief of Gynecologic Oncology Service, associate director for Clinical Research, professor of Interdisciplinary Clinical Oncology, discusses a phase I trial of Vigil personalized engineered autologous tumor cells in ovarian cancer during the 2018 Society of Gynecologic Oncology Annual Meeting.
This novel vaccine involves taking tumor from a patient at the time of surgery and creating a vaccine that is specific to the antigens that are on the patient’s tumor cells, making it fully personalized for that patient, Rocconi explains.
The vaccine also naturally enhances the patient’s immune system, so more of the immune system is able to help fight off cancer cells. Additionally, the vaccine naturally inhibits the suppression secreted by the tumor to decrease recognition by the immune system.
